Connor Clark & Lunn Investment Management Ltd. lifted its stake in Inogen, Inc. (NASDAQ:INGN - Free Report) by 42.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 248,822 shares of the medical technology company's stock after buying an additional 74,197 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 1.04% of Inogen worth $2,282,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. AlphaQuest LLC purchased a new position in shares of Inogen in the fourth quarter worth about $43,000. Quarry LP purchased a new position in shares of Inogen in the third quarter worth about $59,000. Ieq Capital LLC purchased a new position in shares of Inogen in the fourth quarter worth about $94,000. Verition Fund Management LLC purchased a new position in shares of Inogen in the third quarter worth about $106,000. Finally, Virtu Financial LLC purchased a new position in Inogen during the 3rd quarter valued at about $111,000. Hedge funds and other institutional investors own 89.94% of the company's stock.
Inogen Price Performance
NASDAQ:INGN traded down $0.10 during mid-day trading on Friday, reaching $7.35. 321,579 shares of the company's stock traded hands, compared to its average volume of 233,817. Inogen, Inc. has a 12-month low of $6.14 and a 12-month high of $13.33. The firm has a market capitalization of $195.00 million, a price-to-earnings ratio of -3.27 and a beta of 1.15. The company has a 50 day moving average price of $9.75 and a 200-day moving average price of $9.70.
Analyst Ratings Changes
INGN has been the topic of a number of research analyst reports. StockNews.com downgraded Inogen from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th. Needham & Company LLC restated a "hold" rating on shares of Inogen in a report on Wednesday, February 26th.
Get Our Latest Stock Analysis on Inogen
Inogen Company Profile
(
Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
